40 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Apr 2029
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2039 · High confidence
Also notable
Ends Feb 2039 · High confidence
Also notable
Ends May 2040 · High confidence
3-(ETHOXYDIFLUOROMETHYL)-6-(5-Fluoro-6-(2,2,2-Trifluoroethoxy)PYRIDIN-3-YL)-[1,2,4]TRIAZOLO[4,3-a]PYRAZINE AS AN ION CHANNEL MODULATOR
US 11,014,931
The most cited patent in this portfolio, cited by 30 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS MODULATORS OF SODIUM CHANNEL ACTIVITY
US 11,629,146
Cited by 14 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Ion Channel Modulators
US 11,279,700
Cited by 29 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 11, 2027The maintenance fee for Hemi-Citrate Salts of Gaba-A Positive Allosteric Modulator and Crystalline Form Thereof (US 11,697,669) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 5 fees due Feb 1 to 22, 2027 · next Feb 1
- 1 fee due Mar 26, 2027The maintenance fee for SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS ION CHANNEL MODULATORS (US 11,767,325) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 2 fees due Apr 3, 2027
- 1 fee due Jul 9, 2027The maintenance fee for Ion Channel Modulators (US 11,866,439) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Salts and Crystal Forms of Gaba-A Positive Allosteric Modulator (US 10,562,930) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Compounds and Their Methods of Use (US 11,918,571) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- Sep 23Assignment recorded on 1 record: Martinez Botella, Gabriel and 1 other to Praxis Precision Medicines, Inc. Recorded Sep 23, 2026, executed Mar 8, 2019. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76534, frame 594.
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Ion Channel Modulators | 5 in force | to Jan 2041 |
| Formulations of T-Type Calcium Channel Modulators and Methods of Use Thereof | 4 in force | to Jul 2040 |
| Salts and Crystal Forms of Gaba-A Positive Allosteric Modulator | 3 in force | to Jul 2039 |
| N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers | 3 in force | to Apr 2029 |
| SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS ION CHANNEL MODULATORS | 2 in force | to Jan 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,377,968 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers In force · High confidence | In force | High confidence | |
| US 8,569,344 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers In force · High confidence | In force | High confidence | |
| US 9,096,522 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers In force · High confidence | In force | High confidence | |
| US 11,261,188 | Fused Heteroaryl Compounds, and Methods Thereof for Treating Diseases, Disorders, and Conditions Relating to Aberrant Function of a Sodium Channel In force · High confidence | In force | High confidence | |
| US 11,492,345 | Compounds and Their Methods of Use In force · High confidence | In force | High confidence | |
| US 11,278,535 | Compounds and Their Methods of Use In force · High confidence | In force | High confidence | |
| US 11,713,463 | Compositions and Methods for Increasing Expression of SCN2A In force · High confidence | In force | High confidence | |
| US 11,918,571 | Compounds and Their Methods of Use In force · High confidence | In force | High confidence | |
| US 11,629,146 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS MODULATORS OF SODIUM CHANNEL ACTIVITY In force · High confidence | In force | High confidence | |
| US 11,014,931 | 3-(ETHOXYDIFLUOROMETHYL)-6-(5-Fluoro-6-(2,2,2-Trifluoroethoxy)PYRIDIN-3-YL)-[1,2,4]TRIAZOLO[4,3-a]PYRAZINE AS AN ION CHANNEL MODULATOR In force · High confidence | In force | High confidence |
Also on record, not counted in the 40: 45 applications pending · 16 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.